Therapies are becoming more targeted: in DN, SGLT2 inhibitors, finerenone, and agents against glycation, inflammation, and fibrosis are reshaping management; in HN, anti-inflammatory and microvascular function, enhancing drugs (nitric oxide donors, endothelin antagonists) are under study [136,137]. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.